Tradestie Institutional Equity Comparison Engine
LXRX vs CAPR โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CAPR Overall Edge
CAPR Captures Institutional Edge (4โ0 Pillars ยท 5โ5 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Capricor Therapeutics Inc (CAPR) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, LXRX trades at N/M Forward P/E with -147.4% operating margin (-20.7% YoY revenue) versus CAPR at 78.7x Forward P/E and 0.0% operating margin (-7.9% YoY). In options structure, LXRX sits in BREAKDOWN (8th %ile IV; Dealer Gamma Walls on Pro) against CAPR sits in CONSOLIDATION (89th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
CAPR
LXRX N/M vs CAPR 78.7x Fwd P/E
Growth & Margin Winner
CAPR
Op Margin -147.4% vs 0.0% ยท YoY -20.7% vs -7.9%
Momentum & Technical Winner
CAPR
1Y +21.2% vs +44.3% ยท 52W Pos 41% vs 15%
Options & Structure Winner
CAPR
BREAKDOWN (8th %ile IV) vs CONSOLIDATION (89th %ile IV)
LXRX
NASDAQ
Lexicon Pharmaceuticals, Inc.
Pharmaceutical Preparations
$1.75
-2.51% 1D
Market Cap
$810.3M
1M Return
+14.8%
1Y Return
+21.18%
Forward P/E
N/M
Unified AI Score
37.3 / 100
SELL
Tech 50.0
Fund 33.0
Flow 65.0
Mom 44.0
CAPR
NASDAQ
Capricor Therapeutics Inc
Pharmaceutical Preparations
$8.47
-11.12% 1D
Market Cap
$595.4M
1M Return
+26.23%
1Y Return
+44.29%
Forward P/E
78.7x
Unified AI Score
28.0 / 100
SELL
Tech 50.0
Fund 37.0
Flow 68.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
LXRX +21.18%
CAPR +44.29%
Spread: +25.61 pp (CAPR Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | LXRX Revenue | CAPR Revenue | LXRX Op. Margin | CAPR Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $30M | $0M | -388.5% | -917.0% | LXRX |
| FY2019 | $30M | $0M | 437.5% | -769.5% | LXRX |
| FY2020 | $20M | $0M | -204.2% | -4412.6% | LXRX |
| FY2021 | N/A | $0M | N/A | -8549.9% | CAPR |
| FY2022 | N/A | $0M | N/A | -1163.9% | CAPR |
| FY2023 | $0M | $30M | -15473.0% | -95.6% | CAPR |
| FY2024 | $10M | $20M | -3284.7% | -191.1% | CAPR |
| FY2025 | $50M | N/A | -98.2% | N/A | LXRX |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | LXRX | CAPR | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $810.3M | $595.4M | Larger Scale | LXRX |
| Trailing P/E Ratio Valuation | N/M | 78.7x | Lower Multiple | CAPR |
| Forward P/E Ratio Valuation | N/M | 78.7x | Lower Multiple | CAPR |
| Revenue Growth (YoY) Growth | -20.7% | -7.9% | Higher Growth | CAPR |
| Operating Margin (TTM) Profitability | -147.4% | 0.0% | Higher Margin | CAPR |
| Net Profit Margin Profitability | -161.8% | 0.0% | Higher Margin | CAPR |
| Return on Equity (ROE) Capital Efficiency | -43.9% | -100.5% | Higher ROE | LXRX |
| 52-Week Range Position Momentum | 41% ($1โ$3) | 15% ($3โ$40) | Stronger Trend | LXRX |
| Beta / 30D Volatility Risk Regime | 0.62ฮฒ ยท 60% Vol | 1.52ฮฒ ยท 152% Vol | Lower Realized Risk | LXRX |
| Unified Institutional Score Composite Signal | 37.3 / 100 (SELL) | 28.0 / 100 (SELL) | Higher Composite | LXRX |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full LXRX vs CAPR Buy Guide
LXRX
BREAKDOWN
98d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
8th %ile
IV Regime
Compressed (<25th %ile)
CAPR
CONSOLIDATION
56d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
89th %ile
IV Regime
Extreme (>80th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither LXRX nor CAPR registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.